Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Public Comments topic
No spam. Unsubscribe anytime.
Patients and industry urge transparency, changes at OMMA public comment session
Summary
Multiple public commenters told the OMMA advisory council that the agency must improve transparency, testing accuracy and recall communications; one parent described cannabis as life‑saving for her child and urged legislative attention for first responders.
Several people who signed up for public comment at the Executive Advisory Council meeting described personal and industry impacts of Oklahoma’s medical cannabis rules and urged changes to strengthen patient safety and rulemaking.
"This oil has been a life‑saving oil for my son," said Angela Johnson, who told the council she and her son have used medical cannabis to avoid a feeding tube and to manage PTSD. She urged lawmakers to consider legislation that would allow first responders to choose plant‑based medicines when off duty.
Industry speakers pressed OMA on testing, transparency and oversight. Jeff Havard of Havard Industries warned of "THC potency inflation" in products on shelves and said a recent April report shows inflated THC and terpene levels and package shorting. Mohammad Ali Mirambegi (Mo) of Haven Industries said selective transparency and proprietary practices can conceal manipulation and proposed live‑streaming QA lab work to rebuild trust.
Public commenter Summer Parker pressed the agency on restrictions the public faces in recording administrative proceedings and on details about the QA lab’s equipment and ISO status. Jeremy Woods of Woods Compliance asked whether noncompliant-tested products had been placed on administrative hold and whether retesting occurred, citing a June 10, 2024 hold he found in seed‑to‑sale records.
Brandy Keenan, owner of OK Cannabis Consulting and executive director of PCA, praised OMA inspectors’ professionalism but urged commenters to take policy concerns to legislators because many changes require statutory action.
Agency leaders acknowledged the concerns. Executive Director Adria Berry said the agency is building public‑facing web pages for QA lab information and patient education, and that the agency is aligned on the need for accurate testing but constrained where statutory change is required.
The council had no quorum and did not take votes. The next meeting is scheduled for July 17 in room 230.
